Peptide library / Hormones & metabolism / Lanreotide
Lanreotide
A long-acting somatostatin analog injected monthly for acromegaly and neuroendocrine tumors.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- AcromegalyFDA approved
- Gastroenteropancreatic neuroendocrine tumorsFDA approved
How it is thought to work
Lanreotide binds somatostatin receptors on pituitary and tumor cells, suppressing hormone release and slowing tumor growth.
What the evidence shows
In the CLARINET trial, it extended progression-free survival in people with certain neuroendocrine tumors.
Safety and unknowns
Gallstones, diarrhea and injection site reactions are common.
Regulatory status
FDA-approved as Somatuline Depot in 2007, with a tumor indication added in 2014.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Hormones & metabolism
Leuprolide
FDA-approvedA GnRH agonist used to shut down sex hormone production in prostate cancer, endometriosis and early puberty.
Lonapegsomatropin
FDA-approvedA weekly growth hormone prodrug for children with growth hormone deficiency.
Ipamorelin
Wellness and performanceA five amino acid growth hormone secretagogue popular in wellness clinics.
General information, not medical advice. Do not buy or inject unregulated peptides.